Research programme: beta-haemolytic streptococcal vaccineAlternative Names: BHS 019
Latest Information Update: 03 Oct 2011
At a glance
- Originator Wyeth
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Streptococcal infections
Most Recent Events
- 05 Mar 2007 Preclinical trials in Streptococcal infections in USA (unspecified route)